Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks

Dow Jones2021-01-24

MW UPDATE: Fauci says Johnson & Johnson COVID-19 vaccine may get approval in two weeks

By Eileen AJ Connelly

Fauci said the US government was working with different companies on six vaccine candidates, two of which have already gotten the go-ahead for use on an emergency basis, one from Pfizer and the other from Moderna

The first single-dose COVID-19 vaccine could get emergency approval in just two weeks, Dr. Anthony Fauci said late Friday.

"I would be surprised if it was any more than two weeks from now that the data will be analyzed and decisions would be made" about the vaccine being developed by New Jersey-based Johnson & Johnson, Fauci said during an appearance on "The Rachel Maddow Show."

"We'll look at the data and determine if it's ready to be given to the public," Fauci said, "so they can go to the FDA to ask if they can get an emergency use authorization."

Fauci said the US government was working with different companies on six vaccine candidates, two of which have already gotten the go-ahead for use on an emergency basis, one from Pfizer and the other from Moderna. These two both require cold storage and two doses.

The J&J vaccine doesn't have the same need to be kept super-cold, Fauci said, and only requires one dose. Those factors will make a big difference in the ability to get the shots to people, he said. "It gives a wider range of flexibility," he said.

Johnson & Johnson has said it expects to have 100 million doses available by April .

Any additional vaccines made available will be a boost for the city and state, which are running out of doses as New Yorkers scramble for vaccination appointments .

This article was first published on NYPost.com

-; 415-439-6400; AskNewswires@dowjones.com

 

$(END)$ Dow Jones Newswires

January 23, 2021 18:13 ET (23:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
2